← Back to Screener
NewcelX Ltd. Ordinary Shares (NCEL)
Price$3.48
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-4.18%
Price vs S&P 500 (4W)-13.54%
VGM Score52.60
Market Capitalization$18.82M
All Metrics
Book Value / Share (Quarterly)$6.94
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-11.60
Price vs S&P 500 (YTD)74.33%
EPS (TTM)$-5.27
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-5.27
EPS (Annual)$-12.83
ROI (Annual)-140.85%
Cash / Share (Quarterly)$7.40
ROA (Last FY)-88.70%
EBITD / Share (TTM)$-6.71
Cash Flow / Share (Annual)$-13.52
P/B Ratio6.53x
P/B Ratio (Quarterly)4.18x
Net Income / Employee (Annual)$-1,980,800
Net Interest Coverage (TTM)-12.20x
ROA (TTM)-65.92%
EPS Incl Extra (Annual)$-12.83
Current Ratio (Annual)2.69x
Quick Ratio (Quarterly)2.50x
3-Month Avg Trading Volume0.05M
52-Week Price Return-84.96%
Revenue / Employee (TTM)$0
52-Week High$30.80
EPS Excl Extra (Annual)$-12.83
26-Week Price Return11.75%
Quick Ratio (Annual)2.56x
13-Week Price Return22.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.77x
Enterprise Value$15.74M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.27
3-Month Return Std Dev135.54%
Net Income / Employee (TTM)$-2,165,700
ROE (Last FY)-140.85%
Net Interest Coverage (Annual)-33.15x
EPS Basic Excl Extra (Annual)$-12.83
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.27
ROI (TTM)-100.99%
Revenue / Share (Annual)$0.00
Forward P/E0.01x
Price vs S&P 500 (52W)-113.16%
Year-to-Date Return85.26%
5-Day Price Return11.39%
EPS Normalized (Annual)$-12.83
ROA (5Y Avg)-273.89%
Month-to-Date Return-20.18%
EBITD / Share (Annual)$-12.16
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.27
P/B Ratio (Annual)4.65x
Book Value / Share (Annual)$4.45
Price vs S&P 500 (13W)12.90%
Beta0.92x
Revenue / Share (TTM)$0.00
ROE (TTM)-100.99%
52-Week Low$1.83
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Jan 2025
Feb 2025
Mar 2025
Apr 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NCELNewcelX Ltd. Ordinary Shares | — | — | C | $3.48 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
NewcelX Ltd develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases using integrated stem-cell and neuroscience platforms. The company targets major unmet medical needs including ALS and Type 1 Diabetes through regenerative treatment approaches. Headquartered in Ness Ziona, Israel, NewcelX seeks to deliver scalable solutions to significant patient populations.